Physician profile

John Calvin Sharp

Cardiovascular Disease · Hilton Head Island, SC

NPI 1780673830

$10,695.21

in general payments reported to CMS, 2019-2025

38 companies · $1,930 in 2025

The $1,930 reported for 2025 was more than what 83% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$5,166.43

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Medtronic, INC. $2,741.99 2021-2025 Micra, Cobalt Dr Mri Surescan, Mycarelink
Boston Scientific Corporation $2,165.53 2019-2025 Lux-Dx Insertable Cardiac Monitor, Watchman Flx, Watchman Access System
Novartis Pharmaceuticals Corporation $940.51 2019-2025
Abbott Laboratories $846.74 2019-2025 Jot Dx, Gallant, Optis
E.R. Squibb & Sons, L.L.C. $758.02 2019-2025 Camzyos, Eliquis
Medtronic Vascular, INC. $503.53 2019-2020
Amgen INC. $331.58 2019-2025 Repatha, Repatha
Atricure, INC. $282.66 2022-2025 Epi-Sense Guided Coagulation System With Visitrax
Biotronik INC. $215.96 2019-2025 Acticor 7 Vr-T Dx
Janssen Pharmaceuticals, INC $199.48 2019-2023 Xarelto
Cardiva Medical, INC. $148.92 2021-2025 Cardiva Vascade Mvp Vvcs 6-12f
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $147.92 2019-2025 Lifevest
Edwards Lifesciences Corporation $132.89 2025 Sapien 3 Ultra Resilia
Actelion Pharmaceuticals US, INC. $130.28 2024-2025 Opsumit, Opsynvi, Uptravi
Boehringer Ingelheim Pharmaceuticals, INC. $123.06 2019-2023 Jardiance
Show all 38 companies
CompanyGeneral paymentsYearsTop products
Pfizer INC. $121.34 2019
Astrazeneca Pharmaceuticals Lp $107.86 2019-2024 Farxiga
Philips North America LLC $95.38 2025 Ambulatory Monitoring & Diagnostics Undivided, Ecc Solutions
Merck Sharp & Dohme LLC $93.43 2023-2025 Verquvo
Chiesi USA, INC. $82.68 2021
Cvrx, INC. $61.49 2021-2024 Barostim Neo System
Irhythm Technologies, INC. $57.25 2022-2024 Zio Xt Patch, Zio Monitor
Shockwave Medical, INC $51.06 2024 Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter
Abiomed $40.17 2025
Astellas Pharma US INC $36.07 2019
Biosense Webster, INC. $33.32 2024 Nuvision Ice Catheter
Regeneron Healthcare Solutions, INC. $25.16 2019
Lundbeck LLC $24.01 2019
Kowa Pharmaceuticals America, INC. $23.34 2020-2021
Alnylam Pharmaceuticals INC. $21.27 2025 Amvuttra
Scpharmaceuticals INC. $21.27 2025
Bayer Healthcare Pharmaceuticals INC. $20.96 2025
Arbor Pharmaceuticals, INC. $20.09 2019
Medicure Pharma INC. $19.66 2021
Vital Connect, INC $19.39 2023 Vitalpatch Rtm
Sanofi-Aventis U.S. LLC $19.37 2019
Novo Nordisk INC $18.18 2025 Wegovy
Convatec INC. $13.39 2024

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

John Calvin Sharp

$10,695.21

in general payments reported 2019-2025

Years
2019-2025
Top company
Medtronic, INC.
Context
The $1,930 reported for 2025 was more than what 83% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).

https://glasscript.com/doctor/80966/john-calvin-sharp

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.